Bot/bal in relapsed refractory MSS metastatic colorectal cancer – a quick summary
Arndt Vogel shared a post on X:
“Botensilimab plus balstilimab in relapsed/refractory MSS mCRC.
Phase 1 trial, 148 heavily pre-treated patients:
- ORR 17%, DCR 61%
- mPFS 3.5, mOS 20.9 mo
- TRAEs 89%
- No response in patients with liver metastases
- New MOA -> promising”
Read further
Source: Arndt Vogel/X
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.